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The production of diesel exhaust particles 
(DEPs) by vehicular traffic is a major con­
tributor to urban particulate matter air pollu­
tion (McClellan 1987; McClellan et al. 1985; 
Sydbom et al. 2001; Torres­Duque et al. 
2008). Inhalation of diesel exhaust is associated 
with cardiovascular diseases (e.g., atherosclero­
sis, arrhythmias, thrombosis) and respiratory 
diseases [e.g., chronic asthma, chronic obstruc­
tive pulmonary disease (COPD), bronchial 
cancer], leading to an increase in mortality 
(Bayram et al. 2006). DEPs form aggregates 
approximately 0.1–0.5 µm in diameter that 
can penetrate into more distal branches of 
the bronchial tree. Because of the large num­
ber of hazardous chemicals that are present 
on DEPs, their pathologic effects on airways 
and lungs are pleiotropic, as documented in 
numerous studies that have focused on various 
pathologic mechanisms. Specifically, DEPs 
have been shown to increase the secretion of 
proinflammatory cytokines, release phosphati­
dylcholine, produce reactive oxygen species 
that lead to oxidative injury, and induce DNA 
damage, any or all of which may compro­
mise lung function (Bayram et al. 2006; Cao 
et al. 2007a; Danielsen et al. 2008; Ghio et al. 
2000; Madden et al. 2000; Nikula et al. 1995; 
Singh et al. 2004; Zhang et al. 2004).
Matrix metalloproteinase­1 [MMP­1; 
Ensembl Gene ID ENSG00000196611 
(Ensembl 2008)] is a zinc­dependent endo­
peptidase that has been shown to exert detri­
mental effects on respiratory health. MMP­1 
is secreted from cells as an inactive precursor 
of the active proteinase, zymogen (Pardo and 
Selman 2005). MMP­1 plays a role in tissue 
remodeling and repair during development, in 
inflammation, and in the invasion, migration, 
and metastasis of malignantly transformed 
cells (Boire et al. 2005; Ishii et al. 2003). A 
polymorphism in the MMP-1 5´­regulatory 
region –1607G(G) exerts a powerful effect on 
transcriptional activation, and the 1607GG 
sequence forms an Ets transcription­factor 
binding site, which acts as a transcriptional 
activator (Brinckerhoff and Matrisian 2002; 
Rutter et al. 1998; Tower et al. 2002).
Activation of MMP-1 has been shown to 
be of great relevance for airway and lung health 
and disease. MMP­1 is involved in airway extra­
cellular matrix degradation and alveolar wall 
stability and is pathogenetically linked to both 
malignant and nonmalignant chronic respiratory 
diseases (Elkington et al. 2005; Mercer et al. 
2004, 2006; National Heart, Lung, and Blood 
Institute 2007; Segura­Valdez et al. 2000), 
including COPD, chronic asthma, emphysema, 
lung tuberculosis, and bronchial carcinoma.
Two studies have examined the putative 
role of DEP­induced MMP-1 activation in 
lung cells. Doornaert et al. (2003) reported 
a decrease in MMP­1 expression when HBE 
cells (16HBE14o­) were exposed to DEPs. In 
contrast, Amara et al. (2007) investigated the 
effects of DEPs on MMP­1 expression in A549 
and NCI­H292 lung epithelial tumor cell lines 
and found it increased and dependent on the 
NADP(H) oxidase/NOX4 redox­dependent 
mechanism. Given these seemingly conflicting 
results and the relevance of increased MMP­1 
expression for human respiratory health, we 
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Ba c k g r o u n d: Diesel exhaust particles (DEPs) are globally relevant air pollutants that exert a detri-
mental human health impact. However, mechanisms of damage by DEP exposure to human respi-
ratory health and human susceptibility factors are only partially known. Matrix metalloproteinase-1 
(MMP-1) has been implied as an (etio)pathogenic factor in human lung and airway diseases such 
as emphysema, chronic obstructive pulmonary disease, chronic asthma, tuberculosis, and bronchial 
carcinoma and has been reported to be regulated by DEPs. 
oB j e c t i v e: We elucidated the molecular mechanisms of DEPs’ up-regulation of MMP-1. 
Me t h o d s /re s u l t s: Using permanent and primary human bronchial epithelial (HBE) cells at air–
liquid interface, we show that DEPs activate the human MMP-1 gene via RAS and subsequent acti-
vation of RAF-MEK-ERK1/2 mitogen-activated protein kinase signaling, which can be scaffolded 
by β-arrestins. Short interfering RNA mediated β-arrestin1/2 knockout eliminated formation, 
subsequent nuclear trafficking of phosphorylated ERK1/2, and resulting MMP-1 transcriptional 
activation. Transcriptional regulation of the human MMP-1 promoter was strongly influenced by 
the presence of the –1607GG polymorphism, present in 60–80% of humans, which led to striking 
up-regulation of MMP-1 transcriptional activation. 
co n c l u s i o n: Our results confirm up-regulation of MMP-1 in response to DEPs in HBE and 
provide new mechanistic insight into how these epithelia, the first line of protection against envi-
ronmental insults, up-regulate MMP-1 in response to DEP inhalation. These mechanisms include a 
role for the human –1607GG polymorphism as a susceptibility factor for an accentuated response, 
which critically depends on the ability of β-arrestin1/2 to generate scaffolding and nuclear traffick-
ing of phosphorylated ERK1/2.
key w o r d s : β-arrestin, bronchial epithelia, diesel particles, MAP kinase, MMP-1, MMP-1 pro-
moter polymorphism, urban smog. Environ Health Perspect 117:400–409 (2009).  doi:10.1289/
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addressed this issue in permanent and primary 
human bronchial epithelial (HBE) cells, the 
latter assayed at air–liquid interface, using a 
DEP preparation high in organic content real­
istically generated by diesel engines in cars, 
trucks, buses, locomotives, and boats (Bechtold 
et al. 1985; Hirano et al. 2003).
We found that DEPs led to increased acti­
vation of MMP-1 in BEAS­2B bronchial epi­
thelia and primary HBE cells that was linked 
to specific activation of RAS, which leads to 
activation of RAF­MEK­ERK1/2 signaling. 
Signaling was fully dependent on scaffolding 
by both β­arrestin isoforms, enabling mito­
gen­activated protein (MAP) kinase signaling, 
which activates MMP-1 in the nucleus via 
phosphorylated extracellular signal­regulated 
kinase (phospho­ERK1/2). We also found that 
the regulatory effect of DEPs on the MMP-1 
gene critically involved the –1607GG MMP-1 
promoter polymorphism that is present in 25% 
of Caucasians homozygously, and 50% hetero­
zygously, and with similar frequencies in Asian 
and African­American populations (Fujimoto 
et al. 2002). Thus, in most humans, breathing 
DEP­polluted air may trigger increased MMP-1 
activation in airway epithelia, making them vul­
nerable to chronic airway and lung injury.
Material and Methods
Cell culture and DEPs. BEAS-2B human air-
way epithelial cells. We obtained BEAS­2B 
cells, which are SV­40 adenovirus–trans­
formed immortalized bronchial epithelial 
cells (Agopyan et al. 2003; Ghio and Cohen 
2005; Ke et al. 1988), from American Type 
Culture Collection (Rockville, MD). We used 
cells between passages 65 and 85. Cells were 
maintained in keratinocyte growth media 
(Clonetics, San Diego, CA) supplemented 
with bovine pituitary extract (0.22–1.54 mg/
mL total lipid), human epidermal growth 
factor (5 ng/mL), hydrocortisone (0.5 mg/
mL), ethanolamine (0.1 mM), phospho­ 
ethanolamine (0.1 mM), and insulin (5 mg/
mL). All supplemental tissue culture reagents 
were purchased from Sigma (St. Louis, MO). 
For imaging studies, 1 day before use, cells 
were plated at a density of 1 × 105 cells/mL 
on 12­mm­diameter poly­d­lysine–coated 
glass coverslips (Carolina Biological Supply, 
Burlington, NC).
Primary HBE cells. All investigations 
with primary human cells were approved by 
the institutional review board of the EPA and 
Duke University; all studies complied with all 
applicable requirements of the United States 
and customary international regulations. All 
participants provided written informed consent 
before the study. We obtained HBE cells from 
healthy, nonsmoking adult volunteers by cyto­
logic brushing of the airways during bronchos­
copy (Ghio and Cohen 2005). We grew these 
cells to passage 3 in bronchial epithelial growth 
medium (BEGM) (Clonetics, San Diego, CA), 
plated them on 12­well culture plates with 
collagen­coated filters with a 0.4­µm pore size 
(Trans­CLR; Costar, Cambridge, MA) at a 
density of 1 × 105 cells/filter. The cells were 
maintained in a 1:1 mixture of BEGM and 
HEPES­supplemented Dulbecco’s modified 
Eagle’s medium with singlequot supplements, 
bovine pituitary extracts (13 mg/mL), bovine 
serum albumin (1.5 mg/mL), and nystatin (20 
U/mL) in 0.5 mL in the apical chamber and 
1.5 mL in the basal chamber. Fresh medium 
was provided every 48 hr. Media was removed 
from the apical chamber at least 24 hr before 
use to create an air–liquid interface (Ghio and 
Cohen 2005). For measurement of secreted 
MMP­1, we sampled media from the lower 
compartment. Cells were used 3–5 days after 
passage 3; that is, they did not yet display a 
terminally differentiated phenotype (Turi et al. 
2006). Compared with BEAS­2B permanent 
cells, primary HBE cells maintained in air–liq­
uid interface culture devices had a 5­ to 10­fold 
increased cell density, resulting in 5­ to 10­fold 
increased absolute number of cells per assay.
DEPs and P90 control carbon nano  particles. 
DEPs were the generous gift of D. Costa and I. 
Gilmour at the U.S. Environmental Protection 
Agency (EPA) in Research Triangle Park, NC 
(Singh et al. 2004). The DEPs were generated 
at the U.S. EPA main campus in Research 
Triangle Park (NC, USA) using a 30­kW four­
cylinder Deutz BF4M1008 diesel engine con­
nected to a 22.3 kW Saylor Bell air compressor 
to provide load. The emissions from the engine 
were diluted with filtered air (3:1), the tempera­
ture adjusted to approximately 35°C, and the 
emission directed to a small baghouse (Dustex 
model T6­3.5­9 150 ACFM with nine polyes­
ter felt bags). The emissions were collected by 
a conventional pulsing system (reverse air puls­
ing). While the baghouse was pulse­cleaned, 
DEPs filled the bottom of the baghouse in a 
conical section. After 45 min, the contents were 
emptied and immediately refrigerated. In order 
to simulate a more “realistic” environmental 
condition, “EPA DEP MIX” was generated 
by mixing DEPs collected at three different 
engine operations. The engine and compressor 
were operated at steady state using approxi­
mately 25% of the engine’s rated full load. The 
organic:elemental carbon ratio of DEP MIX 
was estimated to be 0.47, calculated from the 
weight percentage of each DEP in the DEP 
MIX and the measured organic:elemental car­
bon ratio of each filter sample collected from 
the different engine operations using a thermal­
optical carbon analyzer.
Degussa Printex 90 (P90) carbon nano­
spheres were the generous gift of W. Moller 
(GSF  National  Research  Center  for 
Environment and Health, Neuherberg/Munich, 
Germany) (Moller et al. 2005). Investigations at 
GSF have demonstrated that P90 nanoparticles 
comprise relatively “clean” carbon particles, that 
is, very low in organic contamination and low 
in metal/water­soluble contamination. In view 
of this, and because their size is similar to the 
DEP carbonaceous cores, we used P90 nano­
particles as control particles.
We applied DEPs and P90 nanoparticles 
in concentrations between 10 and 100 µg/mL, 
subjected to rigorous vortexing (30 sec) before 
application.
Chemicals/pharmacologics. Pharmacologic 
inhibitors and targeted pathways included 
PD98059 and UO126 to specifically inhibit 
MEK MAP kinase, SB203580 for inhibition of 
p38 MAP kinase, SP600125 for inhibition of 
JNK MAP kinase, and LBT613 and AAL881 
to inhibit RAF (Hjelmeland et al. 2007; 
Sathornsumetee et al. 2006). All chemicals were 
purchased from Tocris (Ellisville, MO), except 
the RAF inhibitors, which were a generous 
gift of D. Batt, (Novartis, Cambridge, MA). 
We chose the concentrations based on recom­
mendations of the supplier (Tocris) or those 
commonly used in previous studies (Ahn et al. 
2003; Walker et al. 2003), usually 5–10 µM, 
except for LBT613, which we used at 1 µM 
(Hjelmeland et al. 2007).
Probing gene expression of MMP-1 by real-
time quantitative reverse transcriptase poly-
merase chain reaction. We quantified relative 
gene expression of MMP-1 in human airway 
epithelial cells using real­time quantitative 
reverse transcriptase polymerase chain reaction 
(qRT­PCR). Total RNA was isolated using 
the RNAeasy kit (Qiagen, Valencia, CA) and 
reverse transcribed to generate oligo­dT–
primed cDNA. MMP-1 primer/probe sets 
were obtained as Taqman predeveloped assay 
reagents [concentrated and preoptimized mix 
of primers and Taqman probe labeled with 
6­carboxy­fluorescein (FAM)] from Applied 
Biosystems (Foster City, CA).Quantitative 
fluoro  genic amplification of cDNA was per­
formed using the ABI Prism 7500 Sequence 
Detection System (Applied Biosystems), 
MMP-1 primer/probe sets of interest, and 
TaqMan Universal PCR Master Mix (Applied 
Biosystems). We determined the relative abun­
dance of mRNA levels from standard curves 
generated from a serially diluted standard pool 
of cDNA prepared from cultured human air­
way epithelial cells. The relative abundance of 
β­actin mRNA was used to normalize levels of 
MMP-1 mRNAs.
Transfection of MMP-1–promoter reporter 
constructs. The human MMP-1 reporter plas­
mids –4400, –3292, –2942, –2002, –1546, 
and –517 used in this study harbored the 
firefly luciferase (fLUC) reporter gene under 
the transcriptional control of the MMP-1 pro­
moter (Mercer et al. 2006; Rutter et al. 1998; 
Tower et al. 2003). 1 µg DNA from promoter 
constructs was transiently transfected using 
ExGen 500 (Fermentas, Glen Burnie, MD) Li et al.
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into BEAS­2B cells and plated in 24­well 
plates. As evidenced by fluorescent reporters, 
transfection efficiency was > 70% (data not 
shown). After transfection, cells were washed 
and incubated for 24 hr with or without DEPs 
and/or chemical modulators. Cell lysates were 
generated using 25 mM Tris (pH 7.8), 2 mM 
EDTA, 10% glycerol, 2 mM dithiothreitol, 
and 1% Triton X­100 and were subsequently 
assayed for luciferase activity using the Dual 
Luciferase Reporter Assay System (Promega, 
Thousand Oaks, CA), in a 96­well­plate lumi­
nometer (Veritas Microplate Luminometer, 
Turner Biosystems, Mountain View, CA). 
All transfections were carried out in triplicate 
or in quadruplicate, and cells were cotrans­
fected with a promoterless Renilla luciferase 
construct to control for transfection efficiency 
and   toxicity/viability. Data were normalized by 
Renilla activity and presented as mean ± SE.
Immunocytochemistry. For immuno­
fluorescence studies, we preincubated sections 
for 30 min at room temperature in phosphate­
buffered saline (PBS) containing 0.3% Triton 
X­100 (PBS­Triton) and 10% normal don­
key serum. The sections were then incubated 
for 24 hr at 4°C with mouse monoclonal 
MMP­1–specific antibody (MAB901; R&D 
Systems, Minneapolis, MN) that was diluted 
in PBS­Triton and incubated with fluores­
cein iso  thiocyanate–conjugated donkey anti­
mouse IgG (H+L; Jackson Immunoresearch, 
Philadelphia, PA). Fluorescent micrographs 
were recorded using a BX61 Olympus micro­
scope equipped with the respective filter sets or 
a Leica SP2 confocal laser scanning platform. 
Control experiments were conducted using 
identical amounts of nonspecific isotype mouse 
antibody (R&D Systems).
Enzyme-linked immunosorbent assays and 
MMP-1 cleavage activity assay. We initially 
conducted a cytokine multiplex assay (BioPlex 
Hu­27­Plex; Bio­Rad Laboratories, Hercules, 
CA) and a simplified matrix­metalloproteinase 
proteomics array (SearchLight Human MMP 
Arrays 1 and 2; Endogen­Pierce, Rockford, 
IL). In agreement with previous studies 
(Bayram et al. 1998), we found interleukin­6 
(IL­6) to be significantly up­regulated after 
DEP exposure (Figure 1A), thus assuring the 
validity of our cytokine multiplex assay.
We performed MMP­1 enzyme­linked 
immunosorbent assay (ELISA) following stan­
dard protocols (Kim et al. 2005; Peake et al. 
2005). Briefly, to measure MMP­1 in cell cul­
ture supernatant of BEAS­2B cells and in the 
lower compartment of primary airway epithelia 
kept at air–liquid interface, Nunc MaxiSorp 
ELISA plates (eBioscience, Termecula, CA) 
were coated overnight at 4°C with MAB901 
(R&D Systems). Nonspecific binding to plates 
was blocked with 1% bovine serum albumin in 
PBS for 1 hr at room temperature. After wash­
ing the cells with PBS/0.05% Tween 20, culture 
supernatants/fluids and the MMP­1 standard 
dilutions were added to wells for overnight incu­
bation at 4°C. After washing, detection antibody 
(goat anti­human MMP­1, R&D Systems) was 
added for 90 min at room temperature, fol­
lowed by washing and donkey anti­goat IgG 
horse  radish peroxidase–conjugated detection 
antibody for 45 min. A chromogenic ELISA 
substrate (K­blue, Sigma) was then added for 
color development, which was arrested with 
1 M H2SO4. Plates were read at 450 nm in an 
ELISA plate reader using SoftmaxPro software 
(Molecular Devices, Sunnyvale, CA), which led 
directly to determination of MMP­1 concentra­
tions in samples.
MMP­1 cleavage activity was meas­
ured using a commercially available assay 
(SensolytePlus 520; Anaspec, San Jose, CA). In 
this assay, MMP­1 is captured by immobilized 
MMP­1 antibodies, and its proteolytic activity 
is measured by a 5­FAM/QXLTM520 pep­
tide that evokes fluorescent resonance energy 
transfer (FRET), bearing a specific MMP­1 
cleavage site. The fluorescence of 5­FAM, 
which acts as fluoro  phore, is quenched by 
QXLTM520, which acts as a quencher in the 
intact FRET peptide. Upon specific cleavage 
by active MMP­1, the fluorescence of 5­FAM 
is recovered, and the dual emission of 490/520 
nm is monitored.
None of the colorimetric readouts were 
impaired by the use of DEPs as stimulus (data 
not shown).
Western blotting. We performed Western 
blotting using standard methods (Cao et al. 
2007). Briefly, cells were lysed with radio­
immuno  precipitation assay (RIPA) buffer, sepa­
rated on an 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gel, and then transferred to 
polyvinylidene fluoride (PVDF) filters (0.45 µm 
pore; Millipore, Amherst, MA) by semidry blot 
using Tris­glycine/20% methanol transfer buffer. 
Blotted proteins were immuno­detected using a 
two­step antibody­mediated chemiluminescence 
assay using specific antibodies against MMP­1 
(1:1,000; R&D Systems), MEK, ERK1/2, their 
phosphorylated isoforms (1:500 to 1:2,000; Cell 
Signaling Technology, Danvers, MA), and sec­
ondary peroxidase­coupled antibodies (1:5,000; 
Jackson Immunoresearch).
Trafficking assay of phospho-ERK. 
After stimulation with DEPs, we fixed cells 
in 4% paraformaldehyde at 0, 10, 20, 30, 
and 60­min time points. Cells were then 
immuno  labeled for phospho­ERK1/2, using a 
mouse monoclonal phospho­ERK1/2–specific 
Figure 1. Active MMP-1 is secreted from HBE in response to DEPs. (A) Results of MMP and cytokine 
screen of DEP-stimulated BEAS-2B cell supernatant: secretory responses of several MMPs, TIMPs, and 
IL-6 (positive control). Cells were stimulated in triplicate (50 µg/mL DEPs; supernatants pooled after 6 hr). 
(B) After exposure to increasing concentrations of DEPs, secretion of MMP-1 by BEAS-2B cells followed a 
time course and a dose–response pattern by ELISA. P90 nanoparticles served as control; experiment con-
ducted six times. (C) In primary HBE, DEP (100 µg/mL) exposure evoked robust MMP-1 secretion by ELISA. 
Note also the high amount of unstimulated MMP-1 secretion. P90 nanoparticles served as control; experi-
ment conducted in triplicate. (D) MMP-1 immunofluorescence (BEAS-2B, primary HBE cells) identifies 
cell-bound MMP-1 immunoreactivity (green). In BEAS-2B cells, stimulation with P90 nanoparticles does 
not surpass background; DEP stimulation (100 µg/mL) leads to robust up-regulation, uniformly staining 
all cells. Specificity of the DEP MMP-1 response could also be observed in primary HBE cells, yet here a 
more heterogeneous MMP-1 immunoreactivity is apparent. 4’-6’-diamidino-2-phenylindole (DAPI) nuclear 
stain illustrates increased cell density (blue insert in the lower right-hand micrograph). Scale bars = 20 µm 
for MMP-1 immunolabeling, 80 µm for the DAPI. 
*p < 0.05, **p < 0.01, and #p < 0.001 compared with controls.
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antibody (Cell Signaling Technology), which 
was immunodetected by standard second­
ary reagents (Molecular Probes, Invitrogen, 
Carlsbad, CA), using an upright fluores­
cent microscope (Olympus BX61) or a laser 
confocal scanning microscope (Leica SP2). 
Nuclear abundance of phospho­ERK1/2 was 
determined densitometrically on micrographs 
recorded at respective time points with fixed 
image acquisition settings. ImageJ freeware 
was used for analysis (National Institutes of 
Health 2008) and averaged data were plotted 
against time.
β-Arrestin short interfering RNA experi-
ments. These experiments used established 
protocols (Ahn et al. 2003; DeWire et al. 
2007). Briefly, chemically synthesized, double­ 
stranded short interfering RNAs (siRNAs)   
were  purchased  from  Dharmacon 
Research (Lafayette, CO). We derived the 
sequences from Ahn et al. (2003). The 
siRNA sequences targeting β­arrestin­1 
(GenBank accession no. NM_020251; 
National  Center  for  Biotechnology 
Information  2008)  and  β­arrestin­2 
(NM_004313) are 5´­AAAGCCUUCUG­
CGCGGAGAAU­3´ and 5´­AAGGACCGC 
AAAGUGUUUGUG­3´ and correspond 
to positions 439–459 and 201–221, respec­
tively, relative to the start codon. Another 
RNA duplex was synthesized, used as a control 
(5´­AAGUGGACCCUGUAGAUGGCG­ 
3´; position 101–120 from the start codon of 
β­arrestin­1, sequence common to both arres­
tins), and found to have no silencing effects on 
β­arrestin­1 or ­2 expression (Ahn et al. 2003; 
DeWire et al. 2007). BEAS­2B cells were then 
transfected with siRNA using Lipofectamine 
transfection reagent (Invitrogen) following 
established guidelines (Rippmann et al. 2005). 
Forty­eight hours after transfection, cells were 
divided into 24­well plates for MMP-1–fLUC 
reporter gene assays and MMP­1 ELISA of 
the supernatant. All assays were performed in 
triplicates, with two independent experiments. 
For cellular immunodetection of β­arrestin, we 
used a mouse monoclonal antibody that recog­
nizes both arrestin isoforms (BD Bioscience, 
San Diego CA), and for β­arrestin Western 
blot detection, an antibody generously pro­
vided by R. Lefkowitz (Duke University) raised 
against a common region in the C­terminus.
Transfection of dominant-negative RAS. 
We obtained the dominant­negative RAS 
mutant N116Y as a fusion to enhanced green 
fluorescent protein (eGFP) in pcDNA3.1 plas­
mid as a generous gift from R. Yasuda (Duke 
University) (Watanabe et al. 2000; Yasuda 
et al. 2006). This plasmid (500 ng/well in a 
24­well plate) was transfected into BEAS­2B 
cells using ExGen500 DNA transfection 
reagent (Fermentas) according to manufac­
turer instructions.
Statistical analysis. Mean and SEs of quan­
tified outcome parameters after DEP stimu­
lation were compared with their respective 
controls. For experiments involving modula­
tion of the response, we likewise compared the 
increases from stimulation with DEPs alone 
versus DEPs plus inhibitor. Group compari­
sons were accomplished using fixed­effect one­
way analysis of variance (ANOVA) with post 
hoc Scheffe test for multigroup comparisons. 
Minimum significance was set at the 0.05 level.
Results
DEPs increase MMP-1 secretion in human 
permanent and primary bronchial epithelia. 
As a starting point of our investigation, we 
used commercially available multiplex ELISAs 
to screen the supernatant of DEP­exposed 
BEAS­2B airway epithelial cells for up­regula­
tion of proinflammatory mediators. MMP­1 
emerged as the mediator with the strongest 
up­regulation among MMPs. We also found 
IL­6 to be up­regulated, which was previously 
reported for airway cells in response to DEPs 
(Steerenberg et al. 1998), thus validating our 
findings. In addition, there was a slight down­
regulation of several other MMPs as well as 
their endogenous inhibitors, tissue inhibitor of 
metalloproteinase­1 (TIMP­1) and TIMP­2 
(Figure 1A). MMP­1 secretion was increased 
by DEPs as a function of time (2–24 hr) and 
dose (10–100 µg/mL), but not by a compa­
rable concentration of P90 nanoparticles that 
served as inert carbon control particles (Figure 
1B). These findings agree with a recent report 
of MMP­1 up­regulation (Amara et al. 2007) 
but not with the other study reporting conflict­
ing results (Doornaert et al. 2003). MMP­1 
is also strongly up­regulated in primary 
HBE cells assayed at an air–liquid interface 
(Figure 1C, D). Western blotting of BEAS­2B 
cells confirms this result [see Supplemental 
Material, Figure 1 (http://www.ehponline.org/
members/2008/0800311/suppl.pdf)]. Using 
immunocytochemistry, we found that HBE 
cells exhibit a more heterogeneous expression 
pattern of MMP­1 than do BEAS­2B cells 
(Figure 1D). Density of MMP­1–expressing 
cells was higher in HBE than in BEAS­2B 
cells. Nevertheless, we noticed that in unstimu­
lated conditions, HBE cells secrete significantly 
more MMP­1 than do BEAS­2B cells, exceed­
ing a factor 10 to account for increased cell 
density of HBE cells. Finally, we demonstrated 
that secreted protein correlates with specific 
MMP­1 cleavage activity [see Supplemental 
Material, Figure 2 (http://www.ehponline.  org/
members/2008/0800311/suppl.pdf)].
DEPs increase MMP-1 transcription in an 
allele-specific manner. The dose dependency 
and time course of secreted MMP­1 protein 
in response to DEPs suggest transcriptional 
regulation of the MMP-1 gene. Therefore, 
we investigated transcriptional regulation of 
MMP-1 in response to DEPs, and the possible 
role of the human 1607G(G) polymorphism. 
Increased transcription of MMP-1 was con­
firmed by qRT­PCR in BEAS­2B cells stimu­
lated with DEP versus P90 nanoparticles (100 
µg/mL, 24­hr time point; n = 3 independently 
stimulated dishes per group, Taqman real­time 
qRT­PCR methodology; Figure 2A; results 
Figure 2. DEP MMP-1 response increases in an allele-specific manner for the human–1607G(G) MMP-1 promoter polymorphism. (A) In BEAS-2B cells exposed to 
DEPs (100 µg/mL), MMP-1 mRNA formation is increased (vs. P90 nanoparticle control) as evidenced by relative abundance of the MMP-1 transcript, determined 
by Taqman real-time qRT-PCR. Statistically significant up-regulation of MMP-1 mRNA; experiment conducted in triplicate. (B) A 4.4-kb MMP-1 promoter reporter 
gene construct was transfected into BEAS-2B cells. Schematic illustrates the promoter with transcription factor binding sites (left). The large arrow denotes the 
–1607G(G) human polymorphism, which generates an ETS transcription factor binding site for GG; two smaller arrows denote additional upstream ETS binding 
sites. Diagram at right illustrates MMP-1–fLUC reporter gene activity (normalized for Renilla), in relative units (RU). Note that in response to DEPs (100 µg/mL; 24-hr 
incubation; triplicate assays; data based on three or more experiments), fLUC activity was strikingly increased for –1607GG (2G). (C) DNA sequencing of the MMP-1 
promoter, encompassing –1607, from BEAS-2B cells. Like approximately 50% of all humans, BEAS-2B cells have a heterozygous genotype (–1607GG; –1607G). 
In (A), *p < 0.05 up-regulation of MMP-1. In (B), *p < 0.05, and **p < 0.01, significant difference compared with the unstimulated condition.
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consistent with Amara et al. 2007). To examine 
whether increased MMP-1 mRNA abundance 
in response to DEPs is due to increased mRNA 
stability or to increased transcription, we con­
ducted luciferase reporter gene assays using 
the 4.4­kb MMP-1 promoter. We employed 
both isoforms of the promoter, –1607G and 
–1607GG, to elucidate the impact of the 
promoter polymorphism on gene regulation. 
Figure 2B shows that up­regulation of MMP-1 
transcription causes increased MMP-1 mRNA 
abundance. Also, the –1607GG polymorphism 
potentiated MMP-1 transcription. Figure 2C 
shows the genotype of BEAS­2B cells to be 
heterozygous –1607GG; –1607G, indicating 
that transcription of the endogenous MMP-1 
gene in these cells is carried by both alleles.
A recent study on transcriptional regu­
lation of MMP-1 in response to cigarette 
smoke extract, a complex mix of noxious, pro­
oxidative chemicals/irritants (in this respect 
similar to DEPs), reported a distal “tobacco­
response element” from –2.9 to –4.4­kb of 
the MMP-1 promoter. In view of this, we 
transfected a set of luciferase reporters harbor­
ing MMP-1 promoters of varying length [see 
Supplemental Material, Figure 3 (http://www.
ehponline.org/members/2008/0800311/suppl.
pdf)] into BEAS­2B cells and stimulated them 
with DEPs. The 2.9­kb promoter (–1607GG) 
exhibited the highest activity, followed by 
3.3­kb and 4.4­kb promoters. This suggests 
the presence of sequences that function to bind 
transcriptional repressors, in response to DEPs, 
within the “tobacco­response element” (–2.9 
to –4.4 kb). This regulation was appreciable 
for the –1607GG polymorphism. For shorter 
constructs, iterative reduction of the 2.9­kb 
promoter decreased transcriptional activation.
DEPs specifically activate the RAS-RAF-
MEK-ERK1/2 MAP kinase pathway to activate 
MMP-1. Activation of the MMP-1 gene has 
Figure 3. MAP kinase signaling via the RAS-RAF-
MEK-ERK1/2 pathway is necessary for the DEP 
MMP-1 response in HBE. (A–C) MEK inhibition. 
(A and B) Dependence of the DEP MMP-1 response 
on MEK (and ERK1/2): transcriptional activation of 
MMP-1 at 2 hr (A; left) and 24 hr (A; right) in relative 
units (RU), and secretion of MMP-1 at the same 
time points (B). Both responses depend on MAP 
kinase signaling by MEK-ERK1/2, evidenced by the 
effect of UO126 and PD98059 (both 10 µM). (A and 
B; right) For transcription, differences reach statis-
tical significance for the –1607GG MMP-1 polymor-
phism (A; right) For secretion of MMP-1, differences 
caused by MEK inhibitors are statistically signifi-
cant. DEP stimulation was with 100 µg/mL; experi-
ments conducted in triplicate with two independent 
experiments. (C) Effect of MEK inhibitors UO126 and 
PD98059 on primary HBE cells. Note the complete 
prevention of MMP-1 secretion. Experiment car-
ried out in quadruplicate, with 100 µg/mL DEPs.   
(D–F) RAF inhibition with AAL881 and LBT613 down-
regulated transcription of MMP-1 fLUC reporter 
genes. (D) Down-regulation strongest for the 
–1607GG polymorphism. (E) Secretion of MMP-1 
protein from BEAS-2B cells. (F) Secretion of MMP-1 
protein from primary airway epithelia. Experiments 
conducted in triplicate, with at least two indepen-
dent experiments, using 100 µg/mL DEPs. (G and H) 
RAS inhibition [transient transfection of a dominant-
negative (dom-neg) RAS] down-regulated the DEP 
MMP-1 response. (G) Transcriptional activation of 
MMP-1 and secretion of MMP-1 after 24 hr meas-
ured using MMP-1–fLUC assays (4.4-kb MMP-1 
promoter, –1607G and –1607GG). Cells transfected 
with the –1607G polymorphism showed no effect; 
further reduction of transcription for the –1607GG 
polymorphism was statistically significant, yet 
incomplete. (H) Transcriptional activation of MMP-1 
and secretion of MMP-1 after 24 hr measured using 
MMP-1 ELISA. Transfection of dominant-negative 
RAS without DEP stimulation had no effect on 
MMP-1 transcription. Dominant-negative RAS virtu-
ally eliminated MMP-1. Experiment conducted in 
triplicate with two sets of independent experiments.
*p < 0.05, **p < 0.01, and #p < 0.001, indicate significant 
inhibition of the increase caused by DEP. ##p < 0.05, 
†p < 0.01, and ††p < 0.001 indicate statistically significant 
differences from control.
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been shown to be critically linked to mitogen­
activated protein kinase activation (Cao et al. 
2007; Hecht et al. 2007; Pillinger et al. 2007), 
and involvement of MEK­ERK was recently 
reported for DEP­stimulated lung tumor cells, 
depending on NADPH oxidase (Amara et al. 
2007). We used BEAS­2B bronchial epithelial 
cells to explore whether MAP kinases function 
as intracellular signal transducers leading to 
transcriptional activation of MMP-1. This was 
accomplished by inhibiting MEK, JNK, and 
p38 MAP kinases with specific antagonists; 
RAF with novel specific inhibitors, and RAS 
using a dominant­negative genetic construct. 
We used inhibitory compounds on BEAS­2B 
and primary HBE cells, whereas we used the 
RAS dominant­negative gene construct only in 
BEAS­2B cells.
Specific inhibitors of MEK (UO126, 
PD98059) down­regulated transcription 
(Figure 3A), an effect that was more accen­
tuated for the –1607GG polymorphism. In 
keeping with the –1607G;–1607GG genotype 
of BEAS­2B cells, secretion of MMP­1 was 
also profoundly down­regulated in these cells 
(Figure 3B). To examine whether primary 
HBE cells show an identical activation pattern 
of MAP kinases, we inhibited MEK in pri­
mary HBE cells, which also led to a decrease 
in MMP­1 secretion. MEK inhibition led to 
even lower levels of secreted MMP­1 com­
pared with nonstimulated, nontreated cells, 
pointing toward a “tonic drive” along the 
MEK­ERK MAP kinase pathway in these 
cells (Figure 3C). We next examined whether 
RAF functions up­stream of MEK. Inhibition 
of RAF using the novel specific inhibitors 
LBT613 and AAL881 was as effective as MEK 
inhibition (Figure 3D–F). Based on this find­
ing, we examined whether RAF is activated 
by the membrane bound GTPase RAS. In 
order to inhibit RAS, the dominant­negative 
RAS isoform was transfected heterologously 
into BEAS­2B cells, which led to a marked 
down­regulation of the MMP­1 response 
(Figure 3G, H). However, taking into account 
an estimated 60–70% efficiency for transient 
transfection of BEAS­2B cells, as indicated 
by transfection of fluorescent reporter genes 
(data not shown), a partial down­regulation 
of the MMP­1 response indicates a powerful 
impact of dominant­negative RAS on down­
stream RAF signaling. Regarding the specific­
ity of these findings, inhibition of JNK with 
SP600125 and p38 with SB203580 did not 
significantly (p > 0.3) down­regulate tran­
scription of MMP-1 or MMP­1 secretion 
[see Supplemental Material, Figure 4 (http://
www.ehponline.org/members/2008/0800311/
suppl.pdf)]. The fourth known MAP kinase 
pathway, involving ERK5, was also tested 
using phospho­ERK5 Western blot, and it 
was not activated by DEPs (data not shown). 
Thus, we conclude that activation of RAS, 
which leads to RAF­MEK­ERK1/2 MAP 
kinase signaling, but not p38, JNK, or ERK5, 
is selectively implicated in MMP-1 activation.
MMP-1 up-regulation depends on both 
isoforms of β-arrestin. We next examined the 
role of β­arrestins, given their known associa­
tion with RAF­MEK­ERK1/2 signaling (Ahn 
et al. 2003; Dasgupta et al. 2006; DeWire 
et al. 2007; Lohse et al. 1990; McDonald 
et al. 2000). In recognition of the emerging 
role of β­arrestins as scaffolding proteins that 
bind directly to RAF and MEK and indirectly 
to ERK1/2, orchestrating their function in 
a “signalosome” (Naumann et al. 1999), we 
investigated the function of β­arrestins in the 
DEP MMP­1 response by employing a pre­
viously reported β­arrestin–specific siRNA 
(Ahn et al. 2003; DeWire et al. 2007; Lohse 
et al. 1990; McDonald et al. 2000). We used 
BEAS­2B cells because they have been suc­
cessfully subjected to siRNA gene knockdown 
(Cao et al. 2007a; Rippmann et al. 2005). 
Knocking down β­arrestins led to a down­
regu  lation of the targeted proteins and resulted 
in a down­regulation of MMP-1 transcription 
and MMP­1 secretion (Figure 4A,B). MMP­1 
down­regulatory effects of a specific knock­
down for β­arrestin­1 were more noticeable 
than for β­arrestin­2 (Figure 4A,B), yet both 
were statistically significantly different from 
control (p < 0.01 for protein secretion and 
transcriptional activation). However, the most 
complete effect was obtained using combined 
β­arrestin­1 and ­2 targeting, which amounted 
to a protein knockout for both β­arrestins, as 
revealed by Western blot (Figure 4B) and 
led to complete elimination of transcription 
and secretion of MMP-1 and MMP­1. These 
striking effects clearly demonstrate that, in 
response to DEPs, both β­arrestins are neces­
sary for mediating MMP-1 activation.
DEP­evoked formation of phospho­
ERK1/2 and its subsequent transfer to the 
nucleus depends on RAS­RAF­MEK­ERK1/2 
MAP  kinase signaling and β­arrestins. 
β­Arrestins’ function as scaffolds for RAF­
MEK­ERK1/2 has been shown to encompass 
retention of phospho­ERK in the cytoplasm 
(Ahn et al. 2003; DeWire et al. 2007), yet 
in another study, they were associated with 
nuclear translocation of phospho­ERK 
(Kobayashi et al. 2005; Gesty­Palmer et al. 
2005). As a concept, activation of MMP-1 
via phospho­ERK is understood to involve 
nuclear translocation of the latter (Roberts 
and Der 2007; Tower et al. 2002). In order to 
resolve this issue, we established a time course 
for nuclear translocation of phospho­ERK1/2, 
using immunocytochemistry for phospho­
ERK1/2 after stimulation with DEPs.
A time course of phospho­ERK1/2, using 
immunofluorescent labeling, indicated that 
phospho­ERK enters the nuclear compart­
ment as early as 10 min, with a peak at the 
Figure 4. siRNA-mediated knockdown of both β-arrestins eliminates the DEP MMP-1 response. 
(A) Up-regulation of MMP-1 transcription using luciferase reporter genes (4.4-kb promoter, –1607G and 
–1607GG) in response to DEPs (100 µg/mL, 24 hr) and its striking down-regulation after knocking down 
β-arrestin-1 and -2 either separately or in combination. Fold increase for the –1607G promoter (vs. con-
trol stimulation) was considerably weaker and not statistically significantly different. On the other hand, 
the large increase for the –1607GG promoter was robustly reduced for β-arrestin knockdown, with 
β-arrestin-2 exhibiting a slightly weaker effect than β-arrestin-1 and a complete elimination for combined 
knockout. siRNA was transfected 72 hr before DEP stimulation. Experiment conducted in triplicate, with 
two independent experiments. (B) Fold increase of MMP-1 secretion (BEAS-2B cells) after stimulation 
with DEPs (100 µg/mL), and the respective effect of knockdown of β-arrestins. Knockdown for β-arrestin-1 
lowers the MMP-1 response significantly and is stronger than knockdown of β-arrestin-2, with the highest 
impact with both arrestins combined. Western blots show the effect of knockdown of both β-arrestins 
on their respective protein abundance (normalized for β-actin). Pan-arrestin siRNA leads to complete 
β-arrestin knockout. siRNA was transfected 72 hr before DEP stimulation. Experiment conducted in tripli-
cate, with two independent experiments. 
*p < 0.05, **p < 0.01, and #p < 0.001 compared with fold increase obtained for DEP stimulation using control siRNA.
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30 min time point (Figure 5A,B), confirmed 
by confocal laser scanning microscopy [see 
Supplemental Material, Figure 5 (http://www.
ehponline.org/members/2008/0800311/
suppl.pdf)]. These findings are not in keeping 
with the concept of cytoplasmic retention of 
phospho­ERK1/2 by β­arrestins, but rather 
with previously reported experiments that 
demonstrate β­arrestin–dependent nuclear 
translocation (Kobayashi et al. 2005). Our 
data clearly suggest a logical temporal sequence 
that involves early entry of phospho­ERK1/2 
into the nuclear compartment, leading to 
early transcriptional activation of MMP-1. 
These data and their interpretation are in 
good agreement with our 2­hr time point 
findings for activation of the MMP-1 fLUC­
reporter gene (Figure 3A). Using the pres­
ence of nuclear phospho­ERK1/2 at 30 min 
after stimulation as a read­out of the effect 
of DEPs, we found no increase of nuclear 
phospho­ERK1/2 when chemically inhibiting 
RAF and MEK and when knocking out both 
isoforms of β­arrestin (Figure 5C–E). The 
confocal image of β­arrestin knockout cells 
shows a lack of phospho­ERK1/2 staining 
both in nucleus and cytoplasm, and a virtual 
elimination of whole­cell phospho­ERK1/2 
when using Western blotting, with total ERK 
constant. Thus, both β­arrestins are necessary 
for formation of phospho­ERK1/2. Without 
phospho­ERK1/2, there is no nuclear trans­
location and subsequent regulation of MMP-1 
in response to DEPs.
Discussion
Using human airway epithelial cells, we have 
shown that DEPs lead to increased transcrip­
tional activation of the MMP-1 gene and 
subsequent secretion of MMP­1. This mecha­
nism is powerfully boosted by the –1607GG 
polymorphism within the MMP-1 promoter, 
which is present in at least one allele in 
approximately 75% of humans and forms 
a known ETS transcription factor binding 
site (Rutter et al. 1998). Intracellular con­
stituents that carry this signal transduction are 
the MEK­ERK1/2 MAP kinase cascade, with 
necessary upstream activation of RAF and 
RAS (see schematic overview in Figure 6). 
RAF­MEK­ERK1/2 MAP kinase signaling 
is known to be scaffolded by β­arrestins­1 
and ­2. Accordingly, we found that both 
β­arrestins were necessary for formation of 
phospho­ERK1/2, its subsequent trafficking 
to the nucleus, and transcription of MMP-1. 
Thus, our findings are suggestive of a mecha­
nism for this activation. Because MMP­1 has 
been linked to both nonmalignant and malig­
nant respiratory disorders, results presented 
here increase our understanding of how air­
borne DEPs can injure bronchial epithelia, 
sensitize airway sensory nerve afferents, and 
thus damage human airways and lungs in a 
context of several highly relevant respiratory 
disorders e.g., emphysema, COPD, chronic 
asthma, lung tuberculosis, and bronchial car­ 
cinoma (Kim et al. 2004; Mercer et al. 2004; 
Rutter et al. 1998; Torres­Duque et al. 2008).
Two previous investigations reported on 
the phenomenon of DEPs regulating MMP-1 
expression: one reported a decrease (Doornaert 
et al. 2003), and the other an increase (Amara 
et al. 2007). We differ from the study report­
ing a MMP­1 decrease, a discrepancy that 
could possibly be related to particle, cell, 
or MMP­1 ELISA technology. Our results 
are consistent with the other study showing 
DEPs increased MMP­1 activation based on 
an NADP(H) oxidase–dependent pathway 
(for the relevance of DEPs evoking oxidant­
mediated injury, see Amara et al. 2007; 
Bayram et al. 2006; Cao et al. 2007b; Ghio 
et al. 2000; Madden et al. 2000; Zhang et al. 
2004; for using tumor­derived alveolar cells, 
see Amara et al. 2007). Here, we have used 
bronchial epithelial cells, both permanent and 
primary, with the latter assayed at air–liquid 
interface. Of note, studies on the regulation 
of the human MMP-1 gene cannot readily be 
complemented by studies in mice (or rats), 
because rodents do not have a valid ortholog 
of this gene (Brinckerhoff and Matrisian 
Figure 5. Phospho-ERK1/2 is trafficked to the nucleus as an early signaling event of the DEP MMP-1 response. (A) Time course of nuclear phospho-ERK1/2 
after stimulation of BEAS-2B cells with DEPs (100 µg/mL). Nuclear phospho-ERK was detected by immunofluorescence and its abundance was evaluated by 
densitometry of the nucleus (cell numbers indicated beneath each coordinate). (B) Representative micrographs after DEP exposure of nuclear phospho-ERK 
immuno  fluorescence. Arrows indicate DEPs in direct contact with a cell. Western blots below show increased abundance of phospho-ERK in whole-cell lysate. 
(C) Nuclear phospho-ERK1/2 at 0 min and 30 min. A significant increase for DEP stimulation (100 µg/mL) was absent in controls (media, 0.2% DMSO). Chemical 
inhibition of MEK and RAF eliminated generation of a nuclear signal for phospho-ERK (MEK: UO126, PD98059, both used at 10 µM; RAF: 1 µM LBT613 and 10 µM 
AAL881). Eighty cells were analyzed per condition after DEP stimulation, and 40 before stimulation. (D) Knockdown of β-arrestins also eliminated generation of 
a nuclear signal for phospho-ERK. The graph (left) shows quantitation of control siRNA versus anti–pan-arrestin siRNA. The confocal micrographs (right) show 
representative findings. Eighty cells were analyzed for each condition after DEP stimulation, and 40 before stimulation. (E) Western blot as shown in (C) plus the 
corresponding Western blot for whole-cell phospho-ERK. Cell lysates sampled at 60 min.
***p < 0.001 difference from time point 0 min. #p < 0.01 difference from time point 30 min. ## p < 0.01 compared with control. *p < 0.01 reduction of the 0–30 min difference obtained when 
stimulating with DEPs. ### p < 0.01 difference between DEP-stimulated and control-stimulated. †p < 0.001 down-regulation.
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2002). In addition, our DEP preparation con­
tained an increased concentration of organic 
components compared with the DEPs used 
in the study with tumor­derived alveolar cells 
(Amara et al. 2007), thus providing a stimulus 
more realistically reflecting the exhausts from 
road, rail, and ship traffic.
Three particular aspects of the intra  cellular 
signaling mechanisms leading to activation 
of MMP-1 deserve comment. First, we have 
shown that the –1607GG MMP-1 poly­
morphism in the 5´ regulatory region of the 
human MMP-1 gene exerts a dominant influ­
ence on MMP-1 transcription and is more 
effective than the –1607G promoter. From a 
public health perspective, this is highly rele­
vant because, regardless of ethnicity, at least 
one copy of the –1607GG allele is present in 
60–80% of humans (Fujimoto et al. 2002). 
This finding suggests an enhanced susceptibil­
ity to the detrimental effects of DEP inhala­
tion, possibly together with tobacco smoking 
(Mercer et al. 2004, 2006, 2008; Mercer and 
D’Armiento 2006; Torres­Duque et al. 2008), 
which leads to activation of MMP-1, in most 
people that populate habitats with significant 
DEP exposure (Fujimoto et al. 2002).
Second, we have extended our mechanis­
tic understanding of the role of the MEK­
ERK1/2 pathway in up­regulating the MMP-1 
gene in response to DEPs, first reported by 
Boczkowski’s group (Amara et al. 2007). For 
the first time, we demonstrate an essential role 
for RAF and RAS in this signaling. We have 
identified the necessity of MEK­ERK1/2 in 
primary HBE and shown its critical influence 
on transcriptional activation of the MMP-1 
gene that is potentiated by the –1607GG 
allele. In addition, we have shown that after 
DEP exposure, within 30 min, newly gener­
ated phospho­ERK relocates to the nucleus.
Intracellular signaling cascades do not 
simply operate in a diffusely solubilized 
environment within the cytoplasm, but are 
functionally tightly organized by scaffolding 
proteins, which constitute specific “signalo­
somes” for any signaling cascade that func­
tions in response to a specific stimulus 
(DeWire et al. 2007; Gesty­Palmer et al. 
2005). In this respect, our third contribution 
is that the cellular response to DEPs is depen­
dent on cell­growth–related MAP kinases 
that are dependent on both β­arrestins. In 
contrast to the well­documented concept 
of β­arrestin–mediated scaffolding of MAP 
kinase signaling with cytoplasmic retention 
of phospho­ERK (Ahn et al. 2003; DeWire 
et al. 2007), we have observed nuclear trans­
location of phospho­ERK in the presence of 
β­arrestin­1 and ­2, in agreement with a recent 
study that reported nuclear translocation of 
phospho­ERK dependent on β­arrestin­2 in 
immortalized cultured cells transfected with 
the β2 adrenoceptor (Kobayashi et al. 2005). 
Our finding that both β­arrestins are closely 
linked to this MAP kinase pathway has not 
been previously reported. Mechanistically, 
in the absence of both β­arrestins, phospho­
ERK1/2 was not generated (Figure 5D,E). 
The study by Dasgupta et al. (2006) serves as 
an interesting comparison. They examined the 
role of β­arrestin­1–mediated scaffolding in 
lung tumor cells in response to nicotine, with 
the outcome of cell growth. siRNA­mediated 
knockdown of β­arrestin­1 led to nonforma­
tion of phospho­ERK in response to nicotine, 
with subsequent elimination of the growth 
response. β­Arrestin­1 was recruited to the 
nicotinergic acetylcholine receptor, which was 
instrumental for downstream signaling leading 
to activation of RAF. β­Arrestins might func­
tion similarly in bronchial epithelia exposed 
to DEPs, but a) both β­arrestins were nec­
essary for the DEP MMP­1 response, not 
specifically one of them; b) cell lines in the 
study of Dasgupta et al. (2006) were derived 
from bronchial tumors because the focus of 
their study was cell growth of such tumors in 
response to nicotine, a single compound that 
has a specific cognate cell surface receptor; and 
c) Dasgupta et al. (2006) provided evidence 
of a functional and dynamic protein–protein 
Figure 6. Proposed model of DEP-mediated increased expression of MMP-1 by HBE. DEPs lead to activa-
tion of the membrane-bound GTPase RAS, which in turn switches on the MEK-ERK1/2 MAP kinase via RAF 
signaling. Phospho-ERK is translocated to the nucleus, where it activates the MMP-1 gene [transcription 
start site (TSS)]. ETS binding sites in the MMP-1 promoter are significant for this activation, in particular, 
the presence of such a site at position –1607, –1607GG, a known human susceptibility locus for lung and 
airway disease. MMP-1 mRNA is translated, and MMP-1 is secreted into the abluminal bronchial submu-
cosal layer. Although proven for several cell types and stimuli, scaffolding for RAF and MEK by β-arrestins 
via direct binding awaits experimental proof.Li et al.
408  v o l u m e  117 | n u m b e r 3 | March 2009  •  Environmental Health Perspectives
interaction of the nicotinergic acetylcholine 
receptor with β­arrestin­1, but based on their 
data, an additional role for β­arrestin­1 in scaf­
folding RAF­MEK cannot be excluded.
Regarding the potential human health 
issues associated with this study, RAS­mediated 
MAP kinase signaling is a growth­related 
pathway also known to be dysfunctionally 
activated in malignant transformation of 
tumors (Roberts and Der 2007; Sridhar et al. 
2005). In this context, we note that patho­
genesis of bronchial cancer is also linked to 
extracellular­matrix–degrading properties of 
MMP­1, which includes tumor cell growth, 
invasion, and metastatic capability (Pritchard 
et al. 2001; Rutter et al. 1998). Our find­
ings in cultured airway epithelia can thus 
be viewed as a reflection of the well­known 
epidemiologic association between breathing 
polluted, DEP­containing urban smog and 
increased incidence of bronchial cancer in 
humans (Hemminki and Pershagen 1994; 
McClellan et al. 1985; Parent et al. 2007). 
The findings from this study position us favor­
ably to ask whether known cancer risk co­
factors, namely, cigarette smoking and genetic 
predisposition, enhance MMP-1 activation 
in combination with DEP exposure. With 
respect to cigarette smoking, smoke compo­
nents can enhance MMP-1 transcription via 
the –1607GG polymorphism. In the study 
by Mercer et al. (2008), the distal 1­kb of 
the same 4.4­kb promoter that we have used 
here proved to be essential for activation of 
the MMP-1 gene by cigarette smoke extract, a 
“chemico­toxicologic library” of several thou­
sand compounds, in this respect similar to 
DEP­bound chemicals. As in our study, there 
was increased GG­allele stimulus­responsive 
activity. Remarkably in contrast, however, the 
“tobacco­responsive elements” from –2.9 to 
–4.4kb were critical for an increase in activ­
ity in response to cigarette smoke extract, 
whereas our results point to a strikingly 
repressive mode of action [see Supplemental 
Material, Figure 3 (http://www.ehponline.
org/members/2008/0800311/suppl.pdf)]. 
When Mercer et al. (2008) conducted dele­
tion, bioinformatics, and transcription­factor 
binding studies on the distal segment of the 
4.4­kb MMP-1 promoter, they found PEA3 
transcription factors acting as robust repres­
sors, with binding sites at a “tandem” position 
(–3838 and –3824 relative to transcriptional 
start site). PEA3 and its respective tandem 
binding sites are attractive candidates to func­
tion as repressors of MMP-1 transcription 
in the response to DEPs. However, when 
comparing the response profile of the differ­
ent reporter gene constructs of Mercer et al.’s 
study with ours, it is apparent that detailed 
transcriptional regulation of MMP-1 reveals 
different mechanisms, dependent on the 
airway­injury–inducing stimulus. Regarding 
genetic factors as lung cancer risk factors, 
30% of all bronchial carcinomas have muta­
tions in RAS that render its activity more or 
even constitutively active (Roberts and Der 
2007; Sridhar et al. 2005).
In summary, we have elucidated signaling 
mechanisms operative in HBE and how the 
disease­enhancing MMP-1 gene is activated 
in response to DEPs. We provide evidence 
that in primary HBE cells the growth­related 
MAP kinase signaling pathway is critical for 
DEP­evoked up­regulation of MMP-1 and 
subsequent secretion of MMP­1. We also 
present, for the first time, data that this regu­
lation depends on activation of RAS and RAF 
as well as both isoforms of β­arrestin, which 
we found necessary for formation of phospho­
ERK1/2. In the presence of both β­arrestin 
isoforms, phospho­ERK1/2 translocates to 
the nucleus, peaking at 30 min. This cascade 
of events leads to transcriptional activation 
of MMP-1 that is significantly more robust 
for the –1607GG MMP-1 promoter poly­
morphism, present in most humans.
In terms of translational medical implica­
tions, our findings suggest the potential for 
topi  cal delivery of compounds to human air­
ways that can down­regulate RAS­induced 
MAP kinase signaling, culminating in the acti­
vation of MMP-1, which might be of benefit 
for patients at risk of developing ultimately dev­
astating respiratory diseases linked to MMP-1 
dysregulation (Mercer and D’Armiento 2006). 
Such topical applications, in order to inhibit 
MAP kinase signaling, have also been proposed 
recently for cystic fibrosis patients (Boncoeur 
et al. 2008; Roque et al. 2008).
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